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DOI 10.1016/j.ccr.2010.08.010SUMMARYMicrotubule inhibitors are important cancer drugs that induce mitotic arrest by activating the spindle
assembly checkpoint (SAC), which, in turn, inhibits the ubiquitin ligase activity of the anaphase-promoting
complex (APC). Here, we report a small molecule, tosyl-L-arginine methyl ester (TAME), which binds to the
APC and prevents its activation by Cdc20 and Cdh1. A prodrug of TAME arrests cells in metaphase without
perturbing the spindle, but nonetheless the arrest is dependent on the SAC. Metaphase arrest induced
by a proteasome inhibitor is also SAC dependent, suggesting that APC-dependent proteolysis is required
to inactivate the SAC. We propose that mutual antagonism between the APC and the SAC yields a positive
feedback loop that amplifies the ability of TAME to induce mitotic arrest.INTRODUCTION
Microtubule inhibitors such as taxanes and the vinca alkaloids
represent one of the most important classes of cancer drugs,
used in the treatment of breast, ovarian, and lung cancer
(Montero et al., 2005). However, the response of cells to micro-
tubule inhibitors is highly variable (Brito et al., 2008; Gascoigne
and Taylor, 2008; Orth et al., 2008; Shi et al., 2008), potentially
compromising clinical efficacy. How these drugs cause cell
death remains unclear, but induction of mitotic arrest appears
to be a key aspect of the mechanism (Bekier et al., 2009; Huang
et al., 2009). By perturbing the mitotic spindle, these drugs
activate the spindle assembly checkpoint (SAC), which delays
mitotic exit by inhibiting the ubiquitin ligase activity of the
anaphase-promoting complex/cyclosome (APC). In principle,
a compound that directly inhibits APC-dependent proteolysisSignificance
The anaphase-promoting complex (APC) is required for mito
chemotherapy. Here, we identify TAME as a small molecule in
proTAME. Treatment of cells with proTAME causes a surprising
is required for inactivation of the spindle assembly checkpo
microtubule inhibitors do not suppress APC activity as comp
to maintain mitotic arrest, providing an explanation for the kno
Direct APC inhibitors may therefore provide a more uniform an
382 Cancer Cell 18, 382–395, October 19, 2010 ª2010 Elsevier Inc.should arrest cells in mitosis without causing side effects
that result from microtubule inhibition such as peripheral
neuropathy.
The APC is the most complex ubiquitin ligase known, consist-
ing of more than 11 subunits. The activator proteins Cdh1 and
Cdc20 bind to the APC at different cell cycle stages to stimulate
APC-dependent ubiquitination of substrates and their subse-
quent destruction by the 26S proteasome (Peters, 2006). The
activators assist in recruitment of APC substrates and may
also stimulate ligase activity (Yu, 2007). Cdh1 binds to the APC
during G1 to promote degradation of APC substrates during
interphase. In contrast, the initiation of anaphase and exit from
mitosis require Cdc20-dependent ubiquitination of APC sub-
strates such as securin and mitotic cyclins. Prior to anaphase,
the ability of APC-Cdc20 to ubiquitinate certain substrates is
inhibited by the SAC (Musacchio and Salmon, 2007). Unattachedtic exit, making the APC a potential target for antimitotic
hibitor of the APC and develop a cell-permeable derivative,
ly robust mitotic arrest because APC-dependent proteolysis
int (SAC). In contrast, SAC-activating compounds such as
letely. As a result, cells rely on continued protein synthesis
wn variability in cellular response to microtubule inhibitors.
d specific method for inducing mitotic arrest.
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Figure 1. TAME Inhibits APC Activation by
Perturbing Binding of Cdc20 or Cdh1
(A) Structures of TAME and AAME.
(B) TAME induces mitotic arrest in Xenopus ex-
tract. Recombinant cyclin B1/Cdk1 was added to
interphase extract in the presence of compounds.
Cdc27 phosphorylation and cyclin B1 levels were
examined by immunoblot.
(C) TAME inhibits APC activation. Compounds
were added to mitotic Xenopus extract immedi-
ately before APC immunoprecipitation. The activity
of the isolated APC was measured in a reconsti-
tuted assay.
(D) TAME inhibits Cdc20 association with mito-
tic APC. Compounds were added to mitotic Xeno-
pus extract prior to APC immunoprecipitation.
Numbers represent CCD-imaging based-intensity
quantitation of the immunoblot and show
the relative amount of Cdc20 normalized to Cdc27.
(E) TAME inhibits Cdh1 association with interphase
APC. Interphase Xenopus extract was preincu-
bated with compounds for 30 min prior to adding
recombinant Cdh1 and APC immunoprecipitation.
(F) TAME inhibits APC activation by Cdh1. Inter-
phase Xenopus extract was preincubated with
compound for 30 min prior to adding recombinant
Cdh1 and APC immunoprecipitation. The activity
of the isolated APC was measured in a reconsti-
tuted assay.
See also Figure S1.
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Inhibitor of the Anaphase-Promoting Complexkinetochores catalyze the formation of an inhibitory protein
complex, containing the proteins Mad2, BubR1, and Bub3,
that sequesters Cdc20 or interferes with its ability to activate
the APC. Attachment of kinetochores to the mitotic spindle
diminishes their ability to generate an inhibitory signal. Subse-
quently, the SAC-inhibited APC-Cdc20 complex is activated,
by a mechanism that remains incompletely understood.
Because the APC regulates multiple cell-cycle events, it is not
clear whether pharmacological inhibition of its activity will lead
to selective or prolonged arrest in mitosis as is the case with
microtubule inhibitors. Proteasome inhibitors can block APC-
dependent proteolysis without perturbing the mitotic spindle
(Famulski and Chan, 2007), but they also inhibit the degradation
of many other substrates of the ubiquitin-proteasome system,
and therefore also cause cell-cycle arrest during interphase
(Wojcik et al., 1996). It may be difficult to achieve mitotic arrest
by pharmacologic APC inhibition, as RNAi approaches indicate
that Cdc20 expression must be severely reduced to induce
mitotic arrest (Huang et al., 2009; Wolthuis et al., 2008). Even
when the SAC is maximally activated by complete microtubule
depolymerization, some cells escape mitotic arrest due to
residual APC activity (Brito and Rieder, 2006), suggesting that
the SAC cannot fully inhibit the APC during mitosis. For this
reason, microtubule inhibitors may suffer from limited effective-
ness because some cells escape mitotic arrest before dying
(Bekier et al., 2009; Huang et al., 2009). Whether an APC inhibitorCcan better extinguish APC activity and induce a more persistent
mitotic arrest is therefore an important question in contemplating
development of APC inhibitors as a therapeutic strategy for
cancer.
RESULTS
TAME Inhibits APC Activation by Perturbing Activator
Protein Binding
We identified TAME (Figure 1A) in an earlier study (Verma et al.,
2004) as an inhibitor of cyclin proteolysis in mitotic Xenopus egg
extract (IC50 of 12 mM; Figure S1A), but its mechanism of action
has remained unknown. TAME also inhibited cyclin degradation
in interphase extract activated by exogenous Cdh1, but had no
effect on SCF-dependent proteolysis of b-catenin-luciferase
(Verma et al., 2004), indicating that it is not a general inhibitor
of the ubiquitin-proteasome system. Testing of TAMEderivatives
indicated that the tosyl group, arginine, and the methyl ester are
each important for activity (Figures S1B and S1C). Acetyl-L-argi-
ninemethyl ester (AAME; Figure 1A) showed only low activity and
was therefore used as a negative control in subsequent experi-
ments. When added to interphase extract treated with recombi-
nant cyclin B1/Cdc2 complex, TAME, but not AAME, arrested
the extract in mitosis, with stable cyclin B1 and phosphorylated
Cdc27 (Figure 1B). Another APC substrate, cyclin A2, was also
stabilized by TAME in Xenopus extract (data not shown). TAMEancer Cell 18, 382–395, October 19, 2010 ª2010 Elsevier Inc. 383
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Figure 2. TAME Binds to the APC and
Inhibits Binding of the IR Tail of Activator
Proteins
(A) TAME binds Xenopus APC. 3H-TAME was
added to interphase extract or to extract that had
been partially or completely immunodepleted of
APC. Remaining APC was then immunoprecipi-
tated, and the associated radioactivity was mea-
sured by scintillation counting. Residual APC
levels were measured by immunoblot with Cdc27
antibody. Specific binding was calculated as
described in the methods.
(B) Unlabeled TAME competes with 3H-TAME for
binding to Xenopus APC. 3H-TAME was added
to interphase extract with unlabeled TAME or
AAME prior to APC immunoprecipitation.
(C) 3H-TAMEbinds to human APC. The experiment
in 2A was repeated with lysate from asynchronous
HeLa cells.
(D) Schematic of Cdc20, the C-box containing
fragment, and structures of the IR tail and TAME.
(E) TAME inhibits the interaction between the Cdh1
C-terminal IR peptide and the APC. Left: Resin
coupled with cysteine (Ctrl resin), Cdh1 C-terminal
peptide (WT), or the peptide lacking the C-terminal
isoleucine and arginine (DIR) was incubated with
interphase Xenopus extract, washed, and the
amount of bound Cdc27 was analyzed by immu-
noblot. Right: Cdh1 C-terminal resin was incu-
bated with interphase extract in the presence of
compounds and the amount of Cdc27 was
analyzed as above.
(F) TAME does not inhibit the interaction between
the C-box and the APC. A 159 amino acid
N-terminal fragment of Cdc20 containing the
C-box fused to GST (GST-CDC20 N159 WT) or
the same fragment lacking the C-box (GST-
CDC20 N159 DC-box) were bound to glutathione
resin and incubated with mitotic Xenopus extract
in the presence of compounds. Bound Cdc27
was analyzed by immunoblot.
(G) TAME inhibits IR-peptide crosslinking to APC subunits. Purified interphase Xenopus APC was incubated with an IR peptide coupled to a biotin-containing
label-transfer reagent, in the presence or absence of compounds, prior to photocrosslinking. Reaction products were detected by streptavidin-HRP.
See also Figure S2.
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Inhibitor of the Anaphase-Promoting Complexhad no effect on the ability of Xenopus extract to degrade cyclin
B1 that had been preubiquitinated in vitro (Figure S1D), indi-
cating that TAME does not inhibit the proteasome or its ability
to recognize ubiquitinated substrates.
Because the SAC is not active in Xenopus extracts (Minshull
et al., 1994), we reasoned that TAMEmight inhibit cyclin proteol-
ysis by perturbing the APC. Indeed, when TAME was added to
mitotic Xenopus extract during APC isolation, the APC showed
a dramatic loss of activity in a reconstituted ubiquitination reac-
tion (Figure 1C). Consistent with this finding, TAME addition
to extract reduced Cdc20 association with the APC in a dose-
dependent manner (Figure 1D), but did not otherwise affect
APC composition (Figure S1E). TAME also inhibited the binding
of Cdh1 to APC when Cdh1 and TAME were added together to
interphase extract (Figure 1E). The reduction in Cdh1 binding
was accompanied by a reduction in APC activation (Figure 1F).
These findings suggested that TAMEmight block APC activation
by perturbing the interaction between APC and its activator
proteins Cdc20 or Cdh1.384 Cancer Cell 18, 382–395, October 19, 2010 ª2010 Elsevier Inc.To understand how TAMEdisrupts the interaction between the
activator proteins and the APC, we first tested whether TAME
binds to the APC. We added 3H-TAME to interphase Xenopus
extract, or to extract immunodepleted of APC, and then isolated
residual APC with Cdc27 antibodies and measured the amount
of radioactivity associated with the beads.We found that binding
of 3H-TAME correlated with the amount of immunoprecipitated
Cdc27 (Figure 2A). Unlabeled TAME competitively inhibited the
binding of 3H-TAME, whereas AAME did not (Figure 2B). Other
TAME derivatives competed with 3H-TAME for APC binding in
a manner that correlated with their ability to inhibit cyclin-lucif-
erase proteolysis in Xenopus extract (Figure S2A). A similar
approach demonstrated that TAME binds to human APC iso-
lated from HeLa cells (Figure 2C). Together these findings indi-
cate that TAME binds to the APC, potentially explaining its ability
to perturb activator protein association.
To understand how TAME disrupts activator binding to the
APC, we determined whether TAME could inhibit the interaction
between APC andmotifs of the activator proteins that have been
Cdc27
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Figure 3. TAME Inhibits Binding of Wild-Type Cdc20 to the APC, but Not Binding of a DIR Mutant
Mitotic APC immunoprecipitated from Xenopus extract was washedwith XB high salt (500mMKCl) and XB to remove endogenous Cdc20 prior to incubation with
in vitro translated wild-type Xenopus Cdc20 or the DIR mutant. Various competitors were added during incubation as indicated. Unbound proteins were washed
away and bound Cdc20 was analyzed by immunoblot. Numbers represent the amount of Cdc20 normalized to Cdc27.
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Inhibitor of the Anaphase-Promoting Compleximplicated in APC binding, including the C-box (Schwab et al.,
2001) and the C-terminal isoleucine-arginine (IR) tail (Figure 2D;
Burton et al., 2005; Vodermaier et al., 2003). Because TAME
structurally resembles the IR tail of Cdc20 and Cdh1 (Fig-
ure 2D), we hypothesized that TAME might bind to the APC in
the same site normally occupied by the IR tail. Previous work
has demonstrated that a C-terminal 20 amino acid peptide
derived from Cdh1 (‘‘IR peptide’’) is sufficient to isolate Xenopus
APC from interphase extract (Vodermaier et al., 2003). We
confirmed this finding and found that TAME, but not AAME,
was sufficient to block APC recruitment by the IR peptide (Fig-
ure 2E). In contrast, TAME had no effect on recruitment of APC
frommitotic extract by anN-terminal fragment of Cdc20 contain-
ing only the C-box interaction motif (Figure 2F), indicating that
TAME specifically inhibits the IR-tail-dependent interaction.
The APC subunits Cdc27 and APC7 have been implicated in
binding of the IR tail of Cdh1 to the APC (Matyskiela andMorgan,
2009; Vodermaier et al., 2003). To determine whether TAME
could competitively inhibit the binding of the IR-tail to these pro-
teins, we conjugated the IR peptide to a photo-affinity reagent
and performed crosslinking studies with APC immunopurified
from interphase Xenopus extract. Four proteins known to exist
in an APC subcomplex, namely, Cdc27, Cdc16, Cdc23, and
Apc7, were crosslinked in an IR-dependent manner that could
be competed by excess unlabeled IR peptide (Figures S2B and
S2C). At low concentration (20 mM), TAME efficiently inhibited
crosslinking of the IR peptide to Cdc27 and Cdc16 but only
slightly reduced crosslinking to Cdc23 and Apc7 (Figure 2G). At
high concentration (200 mM), TAME strongly inhibited crosslink-
ing to all APC subunits (Figure 2G). Together these findings
support the hypothesis that TAME binds to APC subunits that
recruit the IR tail, thereby preventing activator proteins from
associating with the APC.
To confirm that TAME specifically antagonizes IR-tail-depen-
dent interactions between Cdc20 and the APC, we tested the
ability of TAME to inhibit the binding of Cdc20 to the APC in
a reconstituted system. APC was purified from mitotic Xenopus
extracts and washed with high salt to remove most Cdc20.
Purified mitotic APC was then incubated in reticulocyte lysateCexpressing wild-type or mutant Cdc20, and Cdc20 binding to
APC was measured by coimmunoprecipitation. We found that
efficient binding of Cdc20 to the APC under these conditions
indeed requires the IR-tail, as a mutant lacking these two resi-
dues (Cdc20DIR) did not bind as efficiently to the APC (Figure 3).
TAME also strongly reduced Cdc20 binding to the APC under
these conditions (Figure 3). Importantly, addition of TAME had
no further effect on binding of the Cdc20DIR mutant, confirming
that TAME does not perturb other interactions between Cdc20
and the APC.
We found that TAME addition or IR-tail deletion was not suffi-
cient to fully inhibit Cdc20 association under these conditions.
We suspected that other interactions, such as C-box-dependent
binding, might promote Cdc20 association with the APC,
thereby masking the effect of TAME addition or IR-tail deletion.
Consistent with this hypothesis, we found that addition of a
C-box-containing N-terminal fragment of Cdc20 could compet-
itively inhibit binding of full-length Cdc20 to the APC (Figure 3).
In the presence of the C-box fragment, addition of TAME or dele-
tion of the IR-tail was sufficient to completely suppress Cdc20
association with the APC. These results indicate that both
C-box-dependent and IR-tail-dependent interactions are impor-
tant for Cdc20 binding in these conditions, and that TAME
specifically disrupts the IR-dependent interaction. We conclude
that the target of TAME is the APC, and that it inhibits APC acti-
vation by interfering specifically with IR-tail-dependent interac-
tions between Cdc20 or Cdh1 and the APC.
A TAME Prodrug Inhibits APC-Cdh1 Activation in Cells
Having established the mechanism by which TAME inhibits APC
activation in Xenopus extract, we next wanted to determine
whether TAME inhibits APC activation in human cells. Because
TAME is not cell permeable, we synthesized a TAME prodrug
(proTAME), and its control compound proAAME, by modifying
the guanidino group to produce an N,N’-bis(acyloxymethyl
carbamate) derivative (Figure 4A). Such prodrugs can be pro-
cessed by intracellular esterases to yield the parent compound.
In Xenopus extract, proTAME was indeed rapidly converted to
TAME (Figure S3A), which efficiently inhibited cyclin B-luciferaseancer Cell 18, 382–395, October 19, 2010 ª2010 Elsevier Inc. 385
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Figure 4. ProTAME Inhibits APC Activity in
Xenopus Extract and Inhibits Cdh1-Depen-
dent APC Activity during Interphase in
HeLa Cells
(A) Structures of proTAME and proAAME.
(B) ProTAME inhibits cyclin B-luciferase degrada-
tion in mitotic Xenopus extract. Different concen-
trations of proTAME or proAAME were added to
mitotic Xenopus extract containing cyclin B-lucif-
erase reporter. Samples were collected at 60 min
and the remaining reporter level was measured
by luminescence.
(C) ProTAME blocks Cdh1 association with the
APC. HeLa cells were released from nocodazole
and treated with proTAME in G1. APC was immu-
noprecipitated from cell lysates and the amount of
Cdc27 and Cdh1 was analyzed by immunoblot.
(D) ProTAME restores mitotic entry in Emi1-
depleted cells. HeLa cells were transfected with
control siRNA or Emi1 siRNA and treated with
DMSO or proTAME 24 hr after transfection and
then imaged for 48 hr. About 400 cells were
analyzed in each experiment, and the proportion
that failed to enter mitosis during the 48 hr of
imaging was calculated. Results of three indepen-
dent experiments are shown. Statistical signifi-
cance was calculated using an unpaired t test.
(E) ProTAME causes a mitotic entry delay if added
during S phase. HeLa H2B-GFP cells were
released from a double thymidine block and
proTAME (12 mM) was added at different time
points as indicated. Mitotic entry was monitored
by time-lapse imaging. Cumulative frequency
curves of the time of mitotic entry are shown.
Statistical analysis, including mean, median, sta-
tistical significance, and number of cells analyzed
per condition for all experiments is included in
Table S1.
See also Figure S3.
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Inhibitor of the Anaphase-Promoting Complexproteolysis (Figure 4B). ProTAMEwas also activated efficiently in
HeLa cells, but not in MCF10A cells (Figure S3B).
We first examined whether proTAME could inhibit association
of Cdh1with the APC in cells. We released HeLa cells expressing
H2B-GFP from a nocodazole block and added 12 mM proTAME
after cells had entered G1, when the APC is activated by Cdh1.
We found that addition of proTAME inhibited Cdh1 association
with the APC (Figure 4C) but proAAME did not. However, pro-
TAME was not sufficient to cause premature accumulation
of endogenous APC substrates in G1 or S phase (Figure S3C).
During S phase, when APC substrates are known to be ex-
pressed, the effect of proTAMEmay bemasked by Emi1-depen-
dent inhibition of APC-Cdh1 (Hsu et al., 2002). To test this idea,
we depleted cells of Emi1, which leads to degradation of APC
substrates and prevents mitotic entry (Hsu et al., 2002). We
confirmed that Emi1 depletion prevents mitotic entry, and found
that addition of 12 mMproTAME substantially rescued themitotic
entry defect caused by depletion of Emi1 (Figure 4D). Therefore,
we conclude that proTAME is capable of inhibiting APC-Cdh1
function in cells.
Previous studies have shown that knockdown of Cdh1
induces prolonged S phase and mitotic entry delay in human
cells (Engelbert et al., 2008; Sigl et al., 2009). Consistent with
these findings, proTAME caused a 2 hr delay in mitotic entry386 Cancer Cell 18, 382–395, October 19, 2010 ª2010 Elsevier Inc.when added during release from a double thymidine block (Fig-
ure 4E). However, adding proTAME 6 hr or later after release did
not delay mitotic entry (Figure 4E), suggesting the delay may be
a consequence of inhibiting APC-Cdh1 in S phase. These find-
ings indicate that, although proTAME can inhibit APC-Cdh1 acti-
vation, it has only modest effects on cell cycle progression
during interphase.
ProTAME Induces Mitotic Arrest in the Absence
of Spindle Damage
To examine effects of proTAME treatment on mitosis, we
released HeLa H2B-GFP cells from a double thymidine block
and added proTAME 8 hr after release, a time when proTAME
addition does not delay mitotic entry (Figure 4E). Mitotic duration
was thenmeasured by time-lapse imaging. Cells treatedwith low
doses of proTAME (780 nM or 3 mM) remained in metaphase for
as long as 5 hr, but then proceeded through a normal anaphase,
whereas cells treated with 12 mM proTAME arrested in meta-
phase and subsequently died (Figure 5A). In contrast, treatment
of cells with 12 mM proAAME had no effect. ProTAME greatly
increased mitotic duration in asynchronous hTERT-RPE1 cells
as well, as 6 mM proTAME increased median mitotic duration
to over 8 hr, compared with 24 min in proAAME-treated cells
(Figure S4A). ProTAME had no effect at similar doses in
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A
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Figure 5. ProTAME Induces Mitotic Arrest without
Disrupting the Mitotic Spindle
(A) ProTAME induces mitotic arrest in HeLa cells. Double
thymidine synchronized HeLa H2B-GFP cells were treated
with compounds and analyzed by time-lapse imaging.
Cumulative frequency curves of mitotic duration and cell
fate distributions are shown.
(B) Partial Cdc20 knockdown sensitizes cells to proTAME
treatment. Asynchronous HeLa H2B-GFP cells were trans-
fected with control or Cdc20 siRNA 24 hr prior to treatment
with compounds.
(C) ProTAME stabilizes endogenous APC substrates.
Double thymidine synchronized HeLa cells were treated
with compounds.
(D) ProTAME stabilizes exogenous cyclin B1-GFP and
cyclin A2-GFP in HeLa cells. HeLa H2B-RFP cells trans-
duced with cyclin-GFP adenoviruses were treated with
20 mM proTAME or proAAME, or 150 nM nocodazole.
Bar: 12 mm. Representative cells are shown. For quantita-
tion, the fraction of GFP intensity remaining at 60 min
as compared with the onset of mitosis was determined
(nR 30 individual cells per treatment). Error bars represent
standard error of the mean.
(E) ProTAME does not disrupt mitotic spindles or alter
interkinetochore distance. Asynchronous HeLa cells were
treatedwith compounds for 2 hr and then stainedwith anti-
tubulin (green) and CREST (red) antibody. Representative
images are shown. Bar: 3 mm. Representative images of
kinetochore pairs are shown. Bar: 1.2 mm. Interkinetochore
distance was measured in DMSO or proTAME treated
cells (n = 55, p = 0.23). Error bars represent standard
deviation.
See also Figure S4 and Movies S1–S4.
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Inhibitor of the Anaphase-Promoting ComplexMCF10A cells (data not shown), because the prodrug was not
efficiently activated (Figure S3B).
If proTAME blocks mitotic progression by disrupting the APC-
Cdc20 interaction, then reducing Cdc20 expression should
enhance the mitotic exit delay induced by proTAME treatment.
In control-transfected cells, 4 mM proTAME increased mitotic
duration from 1.0 to 4.8 hr (Figure 5B). However, when Cdc20
levels were reduced by 50% using siRNA-mediated knockdown
(Figure S4B), proTAME prolonged mitotic duration to 19.4 hr
(Figure 5B). This effect was synergistic, because Cdc20 knock-
down by itself only increased mitotic duration to 1.6 hr. These
results show that reducing the expression of Cdc20 strongly
sensitizes cells to the effect of proTAME, consistent with the
APC-Cdc20 interaction as the relevant target of the compound.
We next investigated the effect of proTAME treatment on
degradation of APC substrates. Because the SAC does not
stabilize all APC substrates during mitosis, some substrates
such as cyclin A2, Cdc20, and Nek2A are degraded in cells
treated with microtubule inhibitors (den Elzen and Pines, 2001;
Hayes et al., 2006; Nilsson et al., 2008). In contrast, substrates
such as cyclin B1 and securin are stabilized by SAC activation.Cancer Cell 18, 38If proTAME directly inhibits APC activation, we
predicted it would stabilize all APC substrates
during mitosis, not just those whose stability
depends on the SAC. Consistent with this hypo-
thesis, cells treated with proTAME accumulated
cyclin A2, Cdc20, and Nek2A in addition tocyclin B1 and securin (Figure 5C). These results were confirmed
in live cell imaging experiments, where proTAME stabilized
cyclinA2-GFP but the microtubule depolymerizer nocodazole
did not (Figure 5D). Interestingly, proTAME treatment caused
greater accumulation of cyclin B1-GFP than nocodazole treat-
ment, consistent with proTAME’s ability to directly inhibit APC
activation.
We next assessed the effects of proTAME treatment onmitotic
spindle morphology and chromosome congression and com-
pared this with the effects of treatment of cells with microtubule
inhibitors. Compared with DMSO-treated cells, treatment of
asynchronous HeLa cells with 12 mM proTAME for 2 hr yielded
no measurable differences in mitotic spindle morphology or
interkinetochore distance, indicating that proTAME did not per-
turb establishment of proper kinetochore tension (Figure 5E).
In contrast, treatment of cells with nocodazole or taxol for 2 hr
strongly perturbed spindle organization (Figure 5E). In live cell
imaging experiments, treatment of cells with 3 mM proTAME or
10 mM MG132 caused no delay in chromosome congression
(Figure S4C). Treatment of cells with 10 nM nocodazole or
12 mM proTAME caused a similar mild congression delay of2–395, October 19, 2010 ª2010 Elsevier Inc. 387
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Figure 6. ProTAME-Induced Mitotic Arrest Is SAC
Dependent
(A) ProTAME-induced mitotic arrest is Mad2 dependent.
HeLa H2B-GFP cells were transfected with indicated
siRNAs between rounds of thymidine treatment. Following
release, cells were treated with compounds and analyzed
by time-lapse imaging. A graph of the same data with an
expanded x axis is shown in Figure S5A.
(B) ProTAME rescues the mitotic defect induced by Mad2
knockdown. Asynchronous HeLa H2B-GFP cells were
treated with Mad2 siRNA 24 hr prior to addition of com-
pound. Bar: 10 mm.
(C) ProTAME-induced mitotic arrest is hesperadin sensi-
tive. Double thymidine synchronized HeLa H2B-GFP cells
were treated with compounds 8 hr following release.
(D) UbcH10 or Cdc27 knockdown induces a hesperadin-
sensitive mitotic delay. HeLa H2B-GFP cells were trans-
fected with indicated siRNA between rounds of thymidine
synchronization and treated with hesperadin 8 hr following
release.
See also Figure S5 and Movies S5 and S6.
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effects on themetaphase plate. In cells treated with 10 nM noco-
dazole, the metaphase plate appeared loose and was prone to
bending (Movies S1–S3), whereas in cells treated with 12 mM
proTAME the metaphase plate appeared tight and did not bend
(Movie S4). Importantly, 10 nM nocodazole prolonged mitosis by
only 20 min (data not shown), whereas 12 mM proTAME induced
a mitotic arrest of over 28 hr (Figure 5A). Thus, the mild delay in
congression is not sufficient to explain the ability of proTAME
to arrest cells in mitosis. We conclude that proTAME induces
arrest in metaphase without perturbing the morphology or func-
tion of the mitotic spindle.
ProTAME-Induced Mitotic Arrest Is SAC Dependent
Because TAME directly inhibits the APC, and causes arrest in
metaphasewith kinetochores that develop tension, we predicted
that the proTAME-inducedmitotic arrest in human cells would be
independent of the SAC.Wewere therefore surprised to find that388 Cancer Cell 18, 382–395, October 19, 2010 ª2010 Elsevier Inc.the SAC is in fact essential for the prolonged
mitotic arrest of cells treated with proTAME.
In double-thymidine synchronized cells, Mad2
knockdown greatly shortened the duration of
proTAME-induced arrest, from 24.6 to 1.4 hr
(Figure 6A; Figure S5A). As expected, Mad2
knockdown abrogated nocodazole-induced
arrest, shortening the average mitotic duration
from 30 to 0.6 hr. The Mad2 dependence of
the proTAME-induced arrest was confirmed
by measurement of APC substrate levels in
synchronized cells (Figure S5B).
These experiments also revealed the ability of
proTAME to delay mitotic exit independent of
Mad2, as expected based on TAME’s ability to
directly inhibit APC activation. In Mad2 knock-
down cells, proTAME treatment increased
median mitotic duration from 12 to 84 min (Fig-
ure 6A; Figure S5A). Strikingly, this mitotic exit
delay was sufficient to give Mad2 knockdowncells enough time to build a normal metaphase plate before initi-
ating anaphase, rescuing the chromosome segregation defect
caused by Mad2 knockdown (Figure 6B; Figure S5C; Movies
S5 and S6). The ability of proTAME to restore normal mitotic divi-
sion in cells depleted of Mad2 demonstrates that proTAME is
unlikely to perturb microtubules or interfere with kinetochore
function. The fact that 12 mM proTAME delays mitotic exit by
only 72 min in the absence of the SAC indicates that this dose
of proTAME does not fully inhibit APC activation. The ability of
this dose of proTAME to cause mitotic arrest in SAC-proficient
cells must therefore arise from significant amplification of APC
inhibition by the SAC.
Whereas TAME reduced Cdc20 binding to the APC when
added to Xenopus extracts, proTAME treatment did not
decrease Cdc20 binding to the APC during mitotic arrest in
HeLa cells (data not shown). We suspected that persistent
Cdc20 association might result from the ability of the SAC to
promote IR-tail-independent binding of Cdc20 to the APC. We
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ability of proTAME to disrupt the APC-Cdc20 interaction. Indeed,
when we arrested HeLa cells in mitosis by expression of nonde-
gradable cyclin B, proTAME induced significant dissociation of
Cdc20 from the APC, but only if SAC proteins were depleted
by RNAi (Figure S5D). These results show that a proTAME-
induced mitotic arrest occurs without substantial dissociation
of Cdc20 from the APC, as a consequence of persistent activity
of the SAC.
To further understand the SAC dependence of the proTAME
arrest, we pharmacologically inactivated SAC signaling by
treating cells with hesperadin (Hauf et al., 2003), an inhibitor of
Aurora B kinase. This kinase phosphorylates proteins at kineto-
chores that are not under tension, leading to destabilization
of microtubule-kinetochore interactions and activation of the
SAC (Biggins and Murray, 2001; Cheeseman et al., 2006;
DeLuca et al., 2006). Recent work using phosphospecific anti-
bodies that recognize Aurora B substrates indicates that kinet-
ochore proteins remain phosphorylated at a basal rate during
metaphase (Welburn et al., 2010). We hypothesized that this
basal rate of Aurora B-dependent phosphorylation may produce
a persistent SAC signal during metaphase that contributes to
the proTAME-induced arrest. Three observations are consistent
with this hypothesis. First, hesperadin treatment dramatically
shortened proTAME-induced mitotic arrest (Figure 6C) and led
to dissociation of Mad2 and BubR1 from the APC in pro-
TAME-arrested cells (Figure S5E). As expected, hesperadin
also substantially shortened taxol-induced mitotic arrest, with
a less pronounced effect on nocodazole-induced arrest (Fig-
ure 6C). Second, hesperadin treatment caused deformation
of the metaphase plate in proTAME-arrested cells (Fig-
ure S5F), suggesting that Aurora B-dependent phosphorylation
is required to maintain proper kinetochore-microtubule attach-
ments in metaphase. Third, knockdown of the APC component
Cdc27 or the APC-specific E2 UbcH10 caused a mitotic exit
delay that could be completely suppressed by hesperadin treat-
ment (Figure 6D). Together, these experiments are consistent
with the idea that the SAC remains active at a basal rate during
metaphase, despite the presence of properly attached chromo-
somes, and that kinetochore-dependent SAC signaling is
important for the prolonged mitotic arrest induced by APC
inhibition.
One possible explanation for the SAC dependence of the
proTAME arrest is that proTAME stabilizes APC substrates
such as Nek2A or cyclin A that are normally degraded in early
mitosis. For example, overexpression of cyclin A has been
reported to delay chromosome congression (den Elzen and
Pines, 2001). To test whether stabilization of these substrates
is important for the proTAME-induced arrest, we released
HeLa cells from double thymidine block into nocodazole for
15 hr to allow degradation of cyclin A and other APC substrates
that are not efficiently stabilized by the SAC. We then washed
cells out of nocodazole into proTAME. Under this condition,
proTAME remained capable of inducing a prolonged mitotic
arrest that was highly hesperadin sensitive (Figure S5G). This
result indicates that the SAC dependence of proTAME-induced
mitotic arrest is unlikely to be caused by stabilization of APC
substrates that are normally degraded in a SAC-independent
fashion.CMetaphase Arrest Induced by a Proteasome Inhibitor
Is SAC Dependent
Previous work has shown that APC-dependent ubiquitination
promotes SAC inactivation in cell lysates (Reddy et al., 2007).
In this system, APC-dependent ubiquitination of Cdc20, but
not APC-dependent proteolysis, was suggested to be important
for release of Cdc20 from SAC proteins (Reddy et al., 2007).
However, a recent study found that proteasome activity is
required for dissociation of the Mad2-Cdc20 complex in cells
(Visconti et al., 2010). Together with our findings, these studies
suggested that APC-dependent proteolysis could be important
for SAC inactivation. A prediction of this model is that mitotic
arrest induced by treatment with a low dose of proteasome
inhibitor should be SAC dependent. To test this idea, we treated
cells with a dose ofMG132 (3 mM) that was just sufficient to arrest
cells in mitosis (median duration of 15 hr). At this concentration,
the duration of arrest was limited by cell death rather thanmitotic
exit, as only 10% of cells exited mitosis over 30h (Figure 7A). In
MG132-treated cells depleted of Mad2 by RNAi, we observed
that 50% of the cells exited mitosis (Figure 7A), indicating that
the SAC is indeed required for efficient induction of mitotic arrest
by proteasome inhibition.
Like proTAME-treated cells, MG132-treated cells arrest
in metaphase with kinetochores that develop normal tension
(Famulski and Chan, 2007). If metaphase chromosomes are
indeed competent to generate a checkpoint signal, we predicted
that the MG132-induced arrest should be hesperadin sensitive.
To test this idea, 10 hr following thymidine release, HeLa H2B-
GFP cells were treated with 3 mM MG132 in the presence or
absence of hesperadin. Strikingly, hesperadin induced rapid
mitotic exit in half of the cells, with the remainder exiting mitosis
more slowly (Figure 7B). These distinct behaviors correlated with
the timing of drug administration: cells that encountered drug
while in mitosis exited mitosis quickly, whereas cells that
encountered drug before mitosis exited slowly (Figure S6A).
Hesperadin treatment induced dephosphorylation of Cdc27 and
reduced levels of Mad2 and BubR1 bound to the APC compared
with cells treated with MG132 alone (Figure S6B). Coaddition of
proTAME to MG132 abrogated the ability of hesperadin to drive
mitotic exit (Figure 7B), indicating that mitotic exit remains
dependent on APC-dependent ubiquitination. In contrast, coad-
dition of taxol to MG132 did not efficiently suppress hesperadin-
induced mitotic exit (Figure 7C), underscoring the distinct mech-
anisms underlying taxol and proTAME-induced mitotic arrests.
Similar results were obtained when the proteasome was more
fully inhibited by increasing the MG132 concentration to 10 mM
(Figure 7D), indicating that the SAC continues to be important
for complete inhibition of APC-dependent proteolysis even when
the proteasome is more completely inhibited by drug.
The hesperadin sensitivity of the MG132-induced arrest
suggested that Aurora B activity could be important for maintain-
ing the metaphase plate, as we observed in proTAME treated
cells. We found that treatment of MG132-arrested cells with hes-
peradin induced deformation of the metaphase plate within
30 min, whereas cells arrested with MG132 alone maintained
a normal-appearing metaphase plate for over 5 hr (Figure S6C).
These findings provide further support for the idea that Aurora
B-dependent pathways remain active in metaphase. Together
our findings indicate that mitotic arrest induced by a lowancer Cell 18, 382–395, October 19, 2010 ª2010 Elsevier Inc. 389
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Figure 7. MG132-Induced Mitotic Arrest Is
SAC Dependent
(A) MG132-induced arrest is Mad2 dependent.
HeLa H2B-GFP cells were transfected with
indicated siRNAs between rounds of thymidine
synchronization, treated with compounds, and fol-
lowed by time-lapse imaging.
(B) MG132-induced arrest is hesperadin sensitive,
but mitotic exit can be suppressed by proTAME.
Double thymidine synchronized HeLa cells were
treated with compounds.
(C) Taxol cannot restore mitotic arrest in the pres-
ence of MG132 and hesperadin. Double thymidine
synchronized HeLa cells were treated with
compounds.
(D) Mitotic arrest induced by a higher concentra-
tion of MG132 remains hesperadin sensitive.
Double thymidine synchronized HeLa cells were
treated with compounds. M: MG132; pT: pro-
TAME; H: hesperadin.
See also Figure S6.
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quence of direct inhibition of the proteasome by the drug, but
also depends on continued inhibition of APC-dependent ubiqui-
tination by the SAC.
Protein Synthesis Is Required for Mitotic Arrest Induced
by Microtubule Inhibitors but Not by APC or Proteasome
Inhibitors
Our data support a model in which APC-dependent proteolysis
is required to inactivate the SAC. However, this model yields
a paradox: How could the APC initiate SAC inactivation if it is fully
inhibited by the SAC? One possibility is that SAC inhibition of
APC is never complete, with residual APC remaining active to
initiate SAC inactivation. Indeed, it has been shown that cyclin
B1 and securin are slowly degraded even in the presence of
a fully active SAC (Brito and Rieder, 2006; Nilsson et al., 2008).390 Cancer Cell 18, 382–395, October 19, 2010 ª2010 Elsevier Inc.Prolonged arrest in mitosis might there-
fore require the continued synthesis of
APC substrates during mitosis. Consis-
tent with this hypothesis, we found that
cycloheximide promoted mitotic exit of
nocodazole- or taxol-arrested cells (Fig-
ure 8A). In striking contrast, cyclohexi-
mide did not accelerate mitotic exit
in proTAME-treated cells, but rather
extended mitotic arrest by delaying cell
death (Figure 8A). Cycloheximide addi-
tion produced similar effects in MG132-
treated cells, suppressing cell death with-
out promoting mitotic exit (Figure 8B).
Consistent with these findings, labeling
experiments demonstrated that known
APC substrates such as cyclin B1 and
BubR1 are translated during mitotic
arrest (Figure S7). Together these findings
indicate that ongoing mitotic protein
synthesis is essential to maintain a SAC-
dependent mitotic arrest, perhaps by
replenishing components that are degraded by residual APC-
dependent proteolysis.
We next wanted to understandwhy theMG132-induced arrest
is resistant to cycloheximide. We hypothesized that persistent
SAC activity cooperates with direct pharmacologic inhibition of
the proteasome to slow the rate of APC-dependent proteolysis
to such a great extent that mitotic arrest no longer depends
upon protein synthesis. If this hypothesis is correct, then inacti-
vating the SAC shouldmake theMG132-induced arrest sensitive
to cycloheximide, as protein synthesis would now be required to
balance the increased rate of APC-dependent degradation. This
was indeed the case, as depletion of Mad2 (Figure 8B) or inacti-
vation of the SACwith hesperadin (Figure 8C) led tomitotic exit in
cells treated with cycloheximide and 10 mM MG132. Addition of
proTAME suppressed the effect of hesperadin (Figure 8C), indi-
cating that mitotic exit remains dependent on APC-mediated
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Figure 8. Microtubule Inhibitors Require
Protein Synthesis forMitotic Arrest whereas
proTAME and MG132 Do Not
(A) Mitotic arrest induced by microtubule inhibitors
requires protein synthesis but proTAME-induced
arrest does not. Double thymidine synchronized
HeLa-H2B-GFP cells were treated with com-
pounds and followed by time-lapse imaging.
CHX: cycloheximide.
(B) MG132 (10 mM)-induced arrest is cyclohexi-
mide resistant but Mad2 dependent. HeLa cells
were transfected with indicated siRNAs between
rounds of thymidine synchronization.
(C) MG132 (10 mM)-induced arrest is cyclohexi-
mide resistant but hesperadin sensitive. Double
thymidine synchronized HeLa cells were treated
with compounds.
(D) Model. In the bottom panels, the x axis indi-
cates time from mitotic entry.
See also Figure S7.
Cancer Cell
Inhibitor of the Anaphase-Promoting Complexubiquitination. Together these results indicate that the ability of
proTAME or MG132 to induce mitotic arrest independent of
protein synthesis requires persistent inhibition of the APC by
the SAC.DISCUSSION
Here, we identify the mechanism of action of a small molecule
inhibitor of cyclin proteolysis discovered in a phenotypic
screen in Xenopus extract (Verma et al., 2004). TAME binds
to the APC and displaces the IR tail of Cdc20 or Cdh1, preventing
efficient APC activation. In human cells, proTAME treatment
causes arrest in metaphase without perturbing the mitotic
spindle. Despite development of normal kinetochore tension
that should silence the SAC, the SAC is required for proTAME
to induce mitotic arrest. Similar results were obtained using
a proteasome inhibitor.We propose that kinetochore-dependentCancer Cell 18, 382–395,SAC signaling persists at a low rate in
metaphase, and is inactivated by residual
APC-dependent proteolysis, creating a
positive feedback loop between the
APC and the SAC (Figure 8D). The ability
of low doses of proTAME or MG132 to
induce metaphase arrest is strongly
enhanced by this feedback loop, enabling
mitotic arrest to be achieved at drug
concentrations below those neces-
sary to fully inhibit the APC or the protea-
some.
TAME Interferes with IR-Tail-
Dependent APC Activation
Our findings indicate that TAME prevents
APC activation by perturbing the binding
of the IR-tail of Cdc20 and Cdh1 to the
APC. The importance of the IR motif in
promoting Cdh1 association with yeast
and human APC is well established (Bur-ton et al., 2005; Kraft et al., 2005; Matyskiela and Morgan,
2009; Vodermaier et al., 2003). However, the role of the
Cdc20 IR motif is less clear, because the Cdc20 IR tail is not
essential in budding yeast (Thornton et al., 2006), and
a Cdc20DIR mutant can support APC-dependent degradation
of Nek2A in Xenopus extract (Kimata et al., 2008). Our data
show that the IR motif of Cdc20 indeed contributes significantly
to APC-association in vitro, as Cdc20DIR binds the APC with
lower affinity than the wild-type protein, and TAME competes
with wild-type Cdc20 for APC association. Moreover, TAME
induces significant dissociation of Cdc20 from the APC in
Xenopus extract, and proTAME can antagonize Cdc20 binding
in human cells if the SAC is inactivated. Functionally, TAME
stabilizes APC substrates in Xenopus extract and proTAME
inhibits both Cdc20 and Cdh1-dependent degradation in
HeLa cells. Taken together, these data show that proper
engagement of the IR motif of Cdc20 or Cdh1 is critical for
APC activation.October 19, 2010 ª2010 Elsevier Inc. 391
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the SAC and the APC
We found that proTAME-induced mitotic arrest requires sus-
tained SAC activity. This finding was unexpected, because pro-
TAME-treated cells arrest in metaphase with kinetochores that
develop normal tension, a condition that should inactivate the
SAC. In principle, the requirement for the SAC in the proTAME
arrest could be explained in one of two ways. First, proTAME
treatment could produce defects in microtubule-kinetochore
interactions that generate an abnormally high degree of check-
point signal compared with normal metaphase kinetochores.
Alternatively, proTAME may hamper SAC inactivation, despite
normal microtubule-kinetochore interactions. We favor the latter
model because the degree of checkpoint dependence far
exceeds the degree of kinetochore-microtubule perturbation
that we observe.
Defects in microtubule-kinetochore attachment could arise
from an off-target effect of TAMEonmicrotubules, or be a conse-
quence of specific APC inhibition. We found that knockdown of
Cdc27 or UbcH10 each produced a mitotic exit delay that was
SAC dependent. Furthermore, treatment of cells with a protea-
some inhibitor yielded a SAC-dependent mitotic arrest, consis-
tent with a recent study showing that MG132-treated mitotic
cells show persistent Mad2-Cdc20 interaction (Visconti et al.,
2010), and work in Schizosaccharomyces pombe showing that
Mad2 and Mad3 remain APC-bound in proteasome mutants
(Ohi et al., 2007). Together these findings suggest that if defec-
tive microtubule-kinetochore interactions are indeed present in
proTAME-treated cells, they are likely to result from specific inhi-
bition of APC-dependent proteolysis rather than from nonspe-
cific effects of proTAME on microtubules.
If defective microtubule-kinetochore interactions exist in
proTAME-treated cells, they must be subtle. Cells treated with
12 mM proTAME arrest in mitosis until they die, yet form a
normal-appearing metaphase plate and develop normal kineto-
chore tension. Furthermore, cells treated with 12 mM proTAME
undergo a normal-appearing anaphase when the SAC is inacti-
vated, indicating that the mitotic spindle functions properly in
the presence of proTAME. The only change in chromosome
behavior caused by this dose of proTAME is a slight delay in
chromosome congression. A lower dose of proTAME (3 mM)
causes no delay in chromosome congression, yet still extends
mitotic duration to 5 hr. Although we cannot completely rule
out subtle defects in microtubule-kinetochore interactions in
proTAME-treated cells, we believe such defects are not of suffi-
cient magnitude to explain the strong dependence of the pro-
TAME arrest on the SAC.
The alternative explanation for the SAC dependence of the
proTAME arrest is that APC-dependent ubiquitination or proteol-
ysis is required to inactivate the SAC. Such mutual antagonism
between the APC and the SAC is predicted to create a positive
feedback loop that would amplify the inhibitory effects of pro-
TAME or a proteasome inhibitor in a SAC-dependent manner.
This is what we observed. If the SAC is inactivated by Mad2
depletion, 12 mM proTAME extends mitotic duration by only
72 min, indicating that this dose only partially inhibits APC acti-
vation (consistent with the measured IC50 of 12 mM in Xenopus
extract). However, when the same dose of proTAME is used in
cells with an intact SAC, proTAME extends mitotic duration by392 Cancer Cell 18, 382–395, October 19, 2010 ª2010 Elsevier Inc.23 hr, indicating that the effect of proTAME is greatly amplified
by the SAC. This degree of amplification cannot be explained
by the mild effect of proTAME on chromosome congression,
because a dose of nocodazole (10 nM) that causes a similar
delay in chromosome congression extends mitotic duration by
only 20 min in SAC-proficient cells. Because we obtained similar
results with a proteasome inhibitor, we believe this amplification
is best explained by a requirement for APC-dependent proteol-
ysis to inactivate the SAC.
It is unclear which APC substrates play the most important
role in mediating the mutual antagonism between the APC and
the SAC. APC-dependent ubiquitination of Cdc20 has been
proposed to release the APC from the inhibitory effects of the
SAC (Reddy et al., 2007; Stegmeier et al., 2007). However, this
process does not require proteasome activity in cell lysates
(Reddy et al., 2007), and others argue that Cdc20 ubiquitination
targets Cdc20 for proteasomal degradation in a manner that
sustains the SAC (Ge et al., 2009; Nilsson et al., 2008). Alterna-
tively, many SAC proteins are APC substrates and may need
to be degraded to inactivate the SAC. Consistent with this possi-
bility, expression of a stable BubR1 mutant induces a mitotic
arrest (Choi et al., 2009). Another candidate is cyclin B1, because
it is degraded prior to anaphase (Clute and Pines, 1999) and
cyclin-dependent kinase activity is required to maintain the
SAC (Chung and Chen, 2003; D’Angiolella et al., 2003). Other
SAC proteins, including Mps1, Bub1, and Aurora B are also
APC substrates, but their bulk population is not degraded until
after anaphase (Palframan et al., 2006; Qi and Yu, 2007; Stewart
and Fang, 2005). It is possible that degradation of these proteins
prior to anaphase is masked by their resynthesis. The mutual
antagonism between the APC and the SAC may reflect a
system-level behavior that is regulated by small changes in the
abundance of multiple SAC proteins prior to anaphase. If so,
confirmation of our model will require quantitative measure-
ments of the relative rates of synthesis and degradation of
APC substrates that regulate SAC activity.
Our results indicate that it is possible to induce mitotic arrest
without fully inhibiting the APC or the proteasome pharmacolog-
ically. This result was unexpected, because RNAi-based exper-
iments indicated that Cdc20 must be reduced to very low levels
to induce mitotic arrest (Wolthuis et al., 2008). Unlike the pro-
TAME-induced arrest, the mitotic arrest induced by Cdc20
knockdown does not depend on the SAC (Huang et al., 2009).
One possible explanation for the lack of SAC dependence in
the context of Cdc20 depletion is that Cdc20 is the target
of the SAC (Yu, 2007). Therefore, when Cdc20 levels are
reduced, the SAC is no longer required to inhibit Cdc20 function.
In contrast, other methods of perturbing APC function, including
knockdown of core APC subunits or the E2 enzyme UbcH10, or
proTAME treatment, all produce an arrest that is SAC depen-
dent. This is likely a consequence of the fact that Cdc20 remains
present under each of these conditions.
A Model for Regulation of Mitotic Exit
Based on our findings, we propose the following model (Fig-
ure 8D). A positive feedback loop between the SAC and the
APC has the potential to adopt one of two stable states: high
SAC activity (mitotic arrest) or high APC activity (mitotic exit).
During normal division, it is important that cells do not become
Cancer Cell
Inhibitor of the Anaphase-Promoting Complexpermanently arrested in mitosis. We propose that the SAC does
not fully inhibit the APC during mitosis because residual APC
activity must be preserved to prevent cells from becoming
locked in mitosis. This residual APC activity may explain why
cyclin B1 is degraded prior to the initiation of anaphase (Clute
and Pines, 1999) and during prolonged SAC-dependent mitotic
arrest (Brito and Rieder, 2006; Gascoigne and Taylor, 2008;
Huang et al., 2009; Nilsson et al., 2008). To remain in mitosis
for a prolonged period, a cell may need to continue to resynthe-
size APC substrates that are degraded by residual APC-depen-
dent proteolysis.
During normal mitosis, the development of kinetochore
tension reduces the rate of SAC activation, but SAC activation
is unlikely to be completely suppressed during metaphase.
Anaphase is triggeredwhen the rate of SAC activation falls below
the rate at which APC-dependent proteolysis inactivates the
SAC, tipping the feedback loop toward rapid APC activation
and mitotic exit. The timing of anaphase initiation therefore
depends not only on how kinetochore attachment controls
SAC activation, but also on the level of residual APC activity.
During nocodazole or taxol treatment, the rate of SAC activa-
tion remains above the rate at which the APC inactivates the
SAC, tipping the loop in the direction of APC inhibition, thereby
preventing mitotic exit. Because APC-dependent proteolysis
is not fully inhibited by the SAC, mitotic arrest is dependent
on protein synthesis to resupply APC substrates. If the rate of
protein synthesis is not sufficient, the rate of SAC signal produc-
tion will fall below the rate at which it is inactivated by the APC,
leading to rapid APC activation and mitotic slippage. Therefore,
the rate of protein synthesis in mitosis may be an important
determinant of the duration of mitotic arrest in cells treated
with microtubule inhibitors.
In contrast to microtubule inhibitors, proTAME and MG132
induce mitotic arrest by inhibiting residual APC-dependent
proteolysis rather than by stimulating SAC activation. The
rate of SAC signal production by kinetochores may decline
normally in proTAME- or MG132-treated cells because kineto-
chores develop proper tension. However, because the rate of
residual APC-dependent proteolysis is lowered by proTAME
or MG132, the rate of SAC signal production cannot fall below
the rate at which it is inactivated by APC-dependent proteol-
ysis, leading to mitotic arrest. The strong hesperadin sensitivity
of both proTAME and MG132-induced arrests indicates the
importance of metaphase kinetochores in generating a SAC
signal to sustain mitotic arrest. Compared with microtubule
inhibitors, this mechanism of mitotic arrest shows reduced
dependence on protein synthesis because the rate of residual
APC activity is lower in proTAME and MG132-treated cells,
yielding a lower requirement for protein synthesis to replenish
APC substrates.
An Opportunity for Antimitotic Cancer Therapy
Our study has identified a potential explanation for the variability
in cellular responses to microtubule inhibitors that could limit
their therapeutic effectiveness. Because the SAC does not com-
pletely inhibit the APC, mitotic arrest induced by microtubule
inhibition depends on protein synthesis. As a result, variation in
the rates of protein synthesis among cells may be one factor
that explains the highly variable response of cells to microtubuleCinhibitors. In contrast, cells treated with an APC inhibitor may be
less prone to mitotic slippage because residual APC activity is
inhibited. APC inhibitors may therefore be more effective in
promoting mitotic arrest, inducing a greater proapoptotic effect.
Furthermore, low doses of an APC inhibitor may be useful in
combination with microtubule inhibitors to sustain mitotic arrest
and enhance cell death.EXPERIMENTAL PROCEDURES
A list of reagents, methods of synthesis of proTAME and additional experi-
mental procedures are provided in the Supplemental Information.3H-TAME Binding Assay
3H-TAME (200 nM; 15 Ci/mmol) was added to 100 ml interphase Xenopus
extract or HeLa cell lysate. APCwas immunoprecipitated with Cdc27 antibody
(Santa Cruz, AF3.1) coupled to affiprep beads (Bio-Rad) as previously
described (Kirkpatrick et al., 2006). The beadswere washedwith XB and radio-
activity measured by scintillation counting. Alternatively, 3H-TAME was added
and Cdc27 immunoprecipitation was performed after one or two rounds of
APC immunodepletion. Specific binding was calculated as the difference
between counts associated with Cdc27 antibody beads compared with beads
lacking antibody (mock IP).APC Isolation by IR Peptide or C-Box Fragment and Crosslinking
A cysteine-containing 20 amino acid peptide derived from the C terminus of
Cdh1, or a control peptide lacking the C-terminal isoleucine and arginine resi-
dues, was reduced with TCEP at RT for 15 min and coupled to Ultralink iodoa-
cetyl resin (Pierce). Ten microliters of resin was mixed with 100 ml interphase
Xenopus egg extract and incubated on a rotator for 30 min at 4C. The resin
was then washed with XB (100 mM KCl, 0.1 mM CaCl2, 1 mM MgCl2, and
10 mM HEPES [pH 7.7]) and bound Cdc27 was analyzed by immunoblot. To
investigate the effect of TAME on C-box interactions, a GST fusion protein
containing the N-terminal 159 residues of XenopusCdc20, or the same protein
lacking the C-box, were expressed and purified as described previously
(Kimata et al., 2008). The proteins (10 mg) were preloaded on 5 ml Gluta-
thione-Sepharose 4B resin (GE Healthcare) and incubated with cyclin
B1D90-arrested mitotic Xenopus extract at RT for 30 min in the presence of
1% DMSO, 200 mM TAME, or 200 mM AAME. The resin was then washed
with XB and bound Cdc27 was analyzed by immunoblot. For crosslinking
studies, the Cdh1-derived C-terminal peptide was conjugated to Profound
Mts-Atf-Biotin label transfer reagent (Pierce) and crosslinked as described in
the supplemental experimental procedures.APC-Cdc20/Cdh1 Association Assay
APC was immunoprecipitated from cyclin B1D90-arrested mitotic Xenopus
extract or interphase extract supplemented with 0.5 mg/ml recombinant
Cdh1 as previously described (Kirkpatrick et al., 2006). Compounds were
added to mitotic extract immediately before immunoprecipitating the APC.
Interphase extracts were preincubated with compounds for 30 min before
adding recombinant Cdh1 and immunoprecipitating the APC. The beads
were washed with XB high salt (XB with 500 mM KCl) and then XB, and
bound Cdc27 and Cdc20/Cdh1 were analyzed by immunoblot. Alternatively,
Cdc20 was expressed using an in vitro coupled transcription/translation
reticulocyte lysate system following the manufacturer’s instruction (Promega
L1170). The lysate was diluted with XB so that the concentration of Cdc20
was approximately equal to that of the endogenous Cdc20 in Xenopus
extract. APC was immunoprecipitated from mitotic extract as described
above and the beads were washed with XB high salt and XB. For each
binding assay, 5 ml beads were mixed with 50 ml diluted lysate plus 1 mM
okadaic acid, 0.05% IGEPAL CA-630 and various competitors as indicated
for 30 min with constant shaking. The beads were then washed with XB +
0.05% IGEPAL CA-630 and bound Cdc27 and Cdc20 were analyzed by
immunoblot.ancer Cell 18, 382–395, October 19, 2010 ª2010 Elsevier Inc. 393
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